This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biotech Stock Bubble Talk Deflated By Cost-Conscious Buyers

NEW YORK ( TheStreet) -- Amgen's (AMGN - Get Report) recent acquisition of Onyx Pharmaceuticals (ONXX) sparked a lot of takeover speculation in the biotech sector. Which company would be the next M&A target? Naturally, the rumor mill was busy. Roche (RHHBY) was said to be interested in Alexion Pharmaceuticals (ALXN - Get Report) and then BioMarin (BMRN - Get Report) a few weeks later. Clovis Oncology (CLVS) shares jumped on an unconfirmed media report that the company was actively seeking a buyer. Soon after, Clovis shares fell when reports surfaced about a lack of interest from prospective suitors forced the company to call off the auction.

The problem with Clovis? Its drug pipeline was too immature and its valuation too rich, reportedly.

Assuming the media reports were accurate, Clovis' unsuccessful attempt to sell itself dovetails nicely into the ongoing debate investors are having about biotech stock valuations. With biotech stocks soaring to 52-week highs (all-time highs in many cases) plus the huge number of successful biotech IPOs, the "bubble" word is being thrown around a lot.

Are we currently experiencing a biotech stock bubble?

I say no bubble. Are biotech stock valuations stretched and in need of a healthy dose of consolidation? Yes, but that's a different and less worrisome condition than a biotech stock bubble.

A financial bubble occurs when the price of an asset rises significantly higher than its intrinsic value. The trouble with this definition is intrinsic value is not known, so bubbles are often only identified in retrospect. Bubbles do, however, generate identifiable behaviors: Greater fool theory, extrapolation of previous price action and increased risk taking.

We're not seeing any of those behaviors exhibited by the strategic buyers of biotech assets during the recent spike in M&A activity -- real and rumored.

When Amgen's $120 bid for Onyx was first reported, Onyx shares rose quickly above the offer price because investors expected other suitors with higher, competing offers to roll in. Amgen eventually raised its offer for Onyx to $125 per share but there was no bidding war for the company. Strategic buyers were quite cost conscious, in fact.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
ONXX $0.00 0.00%
AMGN $163.58 0.00%
ALXN $181.34 0.00%
BMRN $120.91 0.00%
CLVS $86.15 0.00%

Markets

DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs